RenovoRx (RNXT)
NASDAQ:RNXT
RNXT Stock Chart & Stats
$0.97
-$0.05(-3.65%)
At close: 4:00 PM EST
$0.97
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.45
Previous CloseN/A
Volume39.72K
Average Volume (3M)288.82K
Market Cap
$43.70M
Enterprise Value$28.63M
Total Cash (Recent Filing)$7.02M
Total Debt (Recent Filing)$107.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue25.50
Enterprise Value/Gross Profit35.97
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$8.00Price Target Upside724.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$4.17M
Bulls Say, Bears Say
Bulls Say
Clinical Trial And Regulatory ApprovalPositive pivotal Phase III trial results could support regulatory approval for the lead therapy and enable wider adoption of intra-arterial chemotherapy with premium pricing.
Commercialization And Direct SalesConverting clinical trial sites into paying customers and direct sales of the FDA-cleared RenovoCath catheter could build market presence and begin generating commercial revenue.
Platform Differentiation And Market ExpansionThe trans-arterial micro-perfusion delivery platform may reduce systemic side effects and has attracted physician interest for other solid tumors, which could expand the addressable market beyond pancreatic cancer.
Bears Say
Commercial Adoption RiskModest and uneven commercialization revenue as centers adopt the technology gradually could delay steady revenue growth and dent investor confidence.
Development And Execution RiskRemaining a clinical-stage company with limited current revenues exposes the business to high development and commercialization risks that could weigh on valuation.
Revenue Performance Vs. ExpectationsQuarterly revenue falling short of analyst expectations highlights uneven sales traction and creates uncertainty for financial performance.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.45 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $43.70M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is May 18, 2026 which is in 46 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RenovoRx have?
RenovoRx has 45,052,708 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (724.74% Upside)
$8.00 (724.74% Upside)
Insider Transactions
Bought Shares
Worth $18.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
-146.61%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$8.00
▲(724.74% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.54% Insiders
4.95% Mutual Funds
10.97% Other Institutional Investors
76.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---